Pharmaceuticals

An investor rights law firm is investigating the $929M sale of Theravance Biopharma, asking if shareholders are getting a fair deal or if the board failed them.

A wave of precision drugs for Nephrotic Syndrome is set to transform patient lives and a quiet $400M market, revealing a major shift in pharma strategy.

Artelo Biosciences advances a novel non-opioid painkiller, using AI to map its effects and potentially revolutionize how we treat chronic pain.

Evommune halts a key drug trial for chronic hives but leans on a strong cash position and a diversified pipeline to navigate the setback.

A new 'radical collaboration' between top cancer centers is leveraging recent drug breakthroughs to develop combination therapies for pancreatic cancer's deadliest mutation.

AMR Clinical's acquisition of ClinOhio isn't just about growth; it's a strategic move in a booming market, promising faster drug development for sponsors.

A new patent for a non-hallucinogenic compound positions Clearmind Medicine to disrupt the multi-billion dollar market for addiction and compulsive disorders.

A new patent in South Korea for a novel breast cancer vaccine offers a potential paradigm shift from treatment to prevention, but the road from patent to patient is long.

With its fibromyalgia drug now on the market, Tonix is expanding its use to MDD, targeting disturbed sleep in a novel approach for millions of patients.

BioCryst is closing its discovery labs to save millions, betting on external partnerships for its next big drug. But what is the hidden cost of this pivot?

The appointment of a supply chain veteran isn't just HR news; it's the key to unlocking a global market for a new heart drug and a lesson in modern strategy.

With a new FDA Fast Track designation, Satellos Bioscience aims to accelerate its unique muscle-regenerating drug for Duchenne, a strategy that could sidestep genetic limitations.

Merck's new HIV drug, IDVYNSO™, gets a crucial boost via a public health deal, signaling a strategic play to reclaim ground in a multi-billion dollar market.

Beyond the hype, Eisai's latest data on at-home Alzheimer's treatment and a new anti-tau drug signals a seismic shift in patient care and market strategy.

Viridian's Lumvoa gains FDA approval for Thyroid Eye Disease, challenging a blockbuster drug and validating DRI Healthcare's unique royalty investment model.

In a major show of biotech investor confidence, Talawar Therapeutics is going public via a SPAC merger, securing $285M to advance its novel bispecific antibody.

For over a million Europeans with Parkinson's, a new drug promises longer periods of symptom control. But the path from regulatory approval to patient is complex.

Positive interim data for a world-first CBD insomnia trial de-risks development, promising a safer alternative to current drugs and igniting global interest.

Early results for AB Science's AB8939 show a 67% response rate in high-risk AML patients, offering a potential breakthrough where other treatments fail.